



HAL
open science

Modeling and characterization of inter-individual variability in CD8 T cell responses in mice

Chloe Audebert, Daphné Laubretton, Christophe Arpin, Olivier Gandrillon, Jacqueline Marvel, Fabien Crauste

► **To cite this version:**

Chloe Audebert, Daphné Laubretton, Christophe Arpin, Olivier Gandrillon, Jacqueline Marvel, et al.. Modeling and characterization of inter-individual variability in CD8 T cell responses in mice. In *Silico Biology*, 2021, 14 (1-2), pp.13-39. 10.3233/ISB-200205 . hal-03136073

HAL Id: hal-03136073

<https://hal.sorbonne-universite.fr/hal-03136073v1>

Submitted on 9 Feb 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Modeling and characterization of inter-individual variability in CD8 T cell responses in mice

Chloe Audebert^{a,b,c,*}, Daphné Laubreton^d, Christophe Arpin^d, Olivier Gandrillon^{a,e},
Jacqueline Marvel^{d,1} and Fabien Crauste^{a,f,1}

^a*Inria Dracula, Villeurbanne, France*

^b*Sorbonne Université, CNRS, Université de Paris, Laboratoire Jacques-Louis Lions UMR 7598, F-75005 Paris, France*

^c*Sorbonne Université, CNRS, Institut de biologie Paris-Seine (IBPS), Laboratoire de Biologie Computationnelle et Quantitative UMR 7238, F-75005 Paris, France*

^d*Centre International de recherche en Infectiologie, Université de Lyon, INSERM U1111, CNRS UMR 5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, 69007 Lyon, France*

^e*Laboratory of Biology and Modelling of the Cell, Université de Lyon, ENS de Lyon, Université Claude Bernard, CNRS UMR 5239, INSERM U1210, 46 allée d'Italie, Site Jacques Monod, 69007 Lyon, France*

^f*Université de Paris, MAP5, CNRS, F-75006, France*

Abstract. To develop vaccines it is mandatory yet challenging to account for inter-individual variability during immune responses. Even in laboratory mice, T cell responses of single individuals exhibit a high heterogeneity that may come from genetic backgrounds, intra-specific processes (*e.g.* antigen-processing and presentation) and immunization protocols.

To account for inter-individual variability in CD8 T cell responses in mice, we propose a dynamical model coupled to a statistical, nonlinear mixed effects model. Average and individual dynamics during a CD8 T cell response are characterized in different immunization contexts (vaccinia virus and tumor). On one hand, we identify biological processes that generate inter-individual variability (activation rate of naive cells, the mortality rate of effector cells, and dynamics of the immunogen). On the other hand, introducing categorical covariates to analyze two different immunization regimens, we highlight the steps of the response impacted by immunogens (priming, differentiation of naive cells, expansion of effector cells and generation of memory cells). The robustness of the model is assessed by confrontation to new experimental data.

Our approach allows to investigate immune responses in various immunization contexts, when measurements are scarce or missing, and contributes to a better understanding of inter-individual variability in CD8 T cell immune responses.

Keywords: ODE dynamical model, nonlinear mixed effect models, inter-individual variability, immune response, CD8 T cells

1. Introduction

The immune response is recognized as a robust system able to counteract invasion by diverse pathogens [1, 2]. However, as a complex biological process,

the dynamical behavior of its cellular components exhibits a high degree of variability affecting their differentiation, proliferation or death processes. Indeed, the abundance of antigen-specific T cells and their location relative to pathogen invasion will affect the dynamics of the response [2–4]. Similarly, the pathogen load and virulence as well as the host innate response will affect the T cell response [5]. Finally, at the cellular level, between-cell variations in protein

*Corresponding author: Chloe Audebert. E-mail: chloe.audebert@sorbonne-universite.fr.

¹These authors contributed equally to this work.




Fig. 1. CD8 T cell counts after vaccinia virus (VV) immunization in mice. Naive CD44-Mki67-Bcl2+ cell counts (upper left), Early Effector CD44+Mki67+Bcl2- cell counts (upper right), Late Effector CD44+Mki67-Bcl2- cell counts (lower left), and Memory CD44+Mki67-Bcl2+ cell counts (lower right) are measured in 59 individuals over 47 days. Measurements of three different mice are highlighted in blue, green and red, whenever they are available. All other measurements are in grey.

content can also generate heterogeneous responses [6]. Genetic variability of the numerous genes controlling the immune response will also be a source of variability among individuals [1]. Even among genetically identical individuals, the response to the same infection can result in highly heterogeneous dynamics [7–9].

Cytotoxic CD8 T cells play an essential role in the fight against pathogens or tumors as they are able to recognize and eliminate infected or transformed cells. Indeed, following encounter of antigen-presenting cells loaded with pathogen or tumor derived antigens, in lymphoid organs, quiescent naive CD8 T cells will be activated. This leads to their proliferation and differentiation in effector cells that have acquired the capacity to kill their targets, and to their ultimate differentiation in memory cells [10, 11]. The CD8 T cell immune response is yet a highly variable process, as illustrated by experimental measurements of cell counts: dynamics of the responses (timing, cell counts) may differ from one individual to another [4, 12, 13], but also depending on the immunogen [3, 7, 9].

The role of genome variability in explaining inter-individual variations of T cell responses has been recently investigated [14, 15] but provided limited

understanding of the observed heterogeneity. Li et al. [15] have focused on correlations between gene expression and cytokine production in humans, and have identified a locus associated with the production of IL-6 in different pathogenic contexts (bacteria and fungi). Ferraro et al. [14] have investigated inter-individual variations based on genotypic analyses of human donors (in healthy and diabetic conditions) and have identified genes that correlate with regulatory T cell responses.

To our knowledge, inter-individual variability characterized by heterogeneous cell counts has been mostly ignored in immunology, put aside by focusing on average behaviors of populations of genetically similar individuals. The use of such methodology, however, assumes that variability is negligible among genetically similar individuals, which is not true [7, 10, 16], see Figure 1. Experimental measurements of *in vivo* immune responses are often limited, due to tissue accessibility. For instance, mice have to be killed to count CD8 T cell numbers in organs, restricting the follow-up of one individual to blood sampling. Also, ethics do not allow everyday bleeding of animals. Hence measurements in peripheral blood are often performed on a restricted number of time points per individual, which probably led to focus more

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94

95 on average dynamics rather than on heterogeneous
96 individual dynamics.

97 In this work, we propose to model and character-
98 ize inter-individual variability based on CD8 T cell
99 counts using nonlinear mixed effects models [17–19].
100 In these models, instead of considering a unique set of
101 parameter values as characteristic of the studied data
102 set, a so-called *population approach* is used based
103 on distributions of parameter values. All individuals
104 are assumed to be part of the same population, and
105 as so they share a common behavior (average behav-
106 ior) while they keep individual behaviors (random
107 effects). Nonlinear mixed effects models are well
108 adapted to repeated longitudinal data. They aim at
109 characterizing and understanding “typical behaviors”
110 as well as inter-individual variations. T cell count
111 measurements, obtained over the course of a response
112 (few weeks), and the large variability they exhibit
113 represent a case study for this approach (see Figure 1).

114 Nonlinear mixed effects models have been used to
115 analyze data in various fields [20], especially in phar-
116 makokinetic studies, and more recently to model cell
117 to cell variability [21, 22] or to study tumor growth
118 [23, 24]. In immunology, Keersmaekers et al. [25]
119 have recently studied the differences between two
120 vaccines with nonlinear mixed effects models and
121 ordinary differential equation (ODE) models for T
122 and B cells. Jarne et al. [26] and Villain et al. [27] have
123 used the same approach to investigate the effect of IL7
124 injections on HIV+ patients to stimulate the CD4 T
125 cell response. None of these works aimed at iden-
126 tifying immunological heterogeneous processes or
127 characterizing the between-individual variability in
128 CD8 T cell responses, rather nonlinear mixed effects
129 models have been used to characterize the average
130 behavior of the cell populations and explain the data.

131 In order to characterize inter-individual variabil-
132 ity based on experimental cell counts, other methods
133 could be considered. First, one could try to estimate
134 individual parameter values by fitting a mathemati-
135 cal model to individual experimental data. The nature
136 of the data we consider here, illustrated in Fig-
137 ure 1, makes this option unrealistic (not enough
138 data per individual). Another approach could be to
139 use individual-based models, yet such models also
140 require to estimate a lot of parameters and individual
141 data in our case do not provide enough information
142 *per se*. Consequently, nonlinear mixed effects models
143 appear to be the most appropriate method to handle
144 sparse individual data.

145 A number of models of the CD8 T cell response
146 based on ODEs have been proposed over the years.

147 Of particular relevance here is the work of De Boer
148 et al. [28], where the model accounts for activated
149 and memory cell dynamics but the influence of the
150 immunogen is imposed. Antia et al. [29] proposed
151 a model based on partial differential equations, that
152 includes immunogen effects and dynamics of naive,
153 effector and memory cells. These works describe dif-
154 ferent subpopulations of CD8 T cells, however most
155 of the time only total CD8 T cell counts are avail-
156 able to validate the models. In Crauste et al. [10], the
157 authors generated cell counts for four subpopulations
158 of CD8 T cells in mice that they used to identify the
159 most likely differentiation pathway of CD8 T cells
160 after immunogen presentation. This approach has led
161 to a model of the average CD8 T cell dynamics in mice
162 after immunization and its representation as a set of
163 nonlinear ODEs. The model consists in a system of
164 ODEs describing the dynamics of naive, early effec-
165 tor, late effector, and memory CD8 T cell subsets and
166 the immunogen.

167 The goal of this article is to propose, analyze and
168 validate a mathematical methodology for describing
169 individual behaviors and the inter-individual variabil-
170 ity observed in CD8 T cell responses, in different
171 immunization contexts. We will rely on a dynamical
172 description of CD8 T cell dynamics, based on a non-
173 linear model, where parameter values are drawn from
174 probability distributions (nonlinear mixed effects
175 model). Starting from the model introduced and vali-
176 dated in [10], we first select a model of the CD8 T cell
177 immune response dynamics accounting for variabil-
178 ity in cell counts by using synthetic then experimental
179 data, generated in different immunization contexts.
180 Second we characterize the main biological processes
181 contributing to heterogeneous individual CD8 T cell
182 responses. Third, we establish that the immunogen-
183 dependent heterogeneity influences the early phase
184 of the response (priming, activation of naive cells,
185 cellular expansion). Finally, we show that besides
186 its ability to reproduce CD8 T cell response dynam-
187 ics our model is able to predict individual dynamics
188 of responses to similar immunizations, hence pro-
189 viding an efficient tool for investigating CD8 T cell
190 dynamics and inter-individual variability.

191 2. Results

192 CD8 T cell counts have been previously
193 experimentally measured and characterized in 4 sub-
194 populations in Crauste et al. [10]: naive (N), early
195 effector (E), late effector (L) and memory (M) cells

(see Section 4.2). Additionally, a mathematical model has been proposed for the description of these data and validated in [10]. Therein, System (3) has been shown to be able to describe average dynamics of CD8 T cell immune responses, when CD8 T cells go through the 4 above-mentioned differentiation stages. In order to describe individual CD8 T cell counts we couple System (3) to a nonlinear mixed effects model that accounts for both population and individual dynamics. This results in a model of CD8 T cell response dynamics that includes more parameters, consequently when fitting this model to new data sets it is mandatory to determine whether all model parameters can be correctly estimated or if some parameters have to be removed and the initial model modified. We first perform this analysis on ideal data, called “synthetic data”, to determine the minimal number of parameters required to fit the model to the data. Synthetic data are generated from simulations of the model, so true parameter values are known and the estimation procedure is performed in a controlled framework. Then, in a second time, we perform again the analysis on real, experimental data, in order to adapt our procedure to realistic data. Finally, we characterize the biological processes depending on the immunization, and we identify model parameters and their corresponding biological processes that vary the most between individuals. Details of the methodology are presented in Sections 4.3 to 4.7.

2.1. Model selection on synthetic data

In [10], System (3) introduced in Section 4.3 has been shown to be able to describe average dynamics of CD8 T cell immune responses, when CD8 T cells go through 4 differentiation stages: naive, early- then late- effector cells, and memory cells (see Section 4.2). Here System (3) is coupled to a nonlinear mixed effects model, leading model parameters to be drawn from a probability distribution. Initially we assume that any parameter can carry inter-individual variability, then the number of parameters is reduced to ensure correct estimations on ideal data. Ideal data are generated by simulating System (3), so parameter values are known (probability distributions). These data sets enable to evaluate the potential of the model without data availability-related limitations: we call them “synthetic data”. Here, synthetic data account for 100 individuals (mice) and measurements are available every day from D4 to D10, then every 2 days from D10 to D20, and finally on D25 and D30 pi, see Table 1 and Section 4.6 for details.

Table 1
Data sets (details in Sections 4.2, 4.3 and 4.6)

Short Name	Description
VV data set 1	CD8 T cell counts of 59 individual mice inoculated intra-nasally with 2×10^5 pfu of a vaccinia virus (VV) expressing the NP68 epitope ; naive, early and late effector, and memory cell counts have been measured up to day 47pi (days 4, 6, 7, 8, 11, 13, 15, 18, 22, 27, 28, 32, 47pi with maximum 15 measurements per time point)
VV data set 2	Similar to VV data set 1 (15 individual mice) ; CD8 T cell counts of naive, early and late effector, and memory cells have been measured following VV immunization, up to day 42pi (days 4, 6, 7, 8, 11, 13, 15, 21, 28, 42pi with maximum 4 measurements per time point)
Tumor data set 1	CD8 T cell counts of 55 individual mice subcutaneously inoculated with 2.5×10^6 EL4 lymphoma cells expressing the NP68 epitope ; naive, early and late effector, and memory cell counts have been measured up to day 47pi (days 4, 5, 6, 7, 8, 10, 11, 13, 14, 15, 18, 22, 27, 32, 46, 47pi with maximum 15 measurements per time point)
Tumor data set 2	Similar to Tumor data set 1 (20 individual mice); CD8 T cell counts of naive, early and late effector, and memory cells have been measured following Tumor immunization, up to day 42pi (days 6, 7, 8, 11, 13, 15, 21, 28, 42pi with maximum 5 measurements per time point)
Synth data sets 1 to 4	Synthetic data sets generated with System (3) and its subsequent simplifications (see Section 4.6), consisting in CD8 T cell counts of naive, early and late effector, and memory cells on days 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30pi for all 100 individuals

We use Synth data sets 1 to 4 (Table 1) to validate the parameter estimation procedure. True parameter values are known and given in Section A1. Parameter estimation is performed with the SAEM algorithm implemented in Monolix software [30]. Using a model selection procedure, based in particular on the use of the relative standard error (RSE) defined in (4) that informs on the confidence in the estimation, we iteratively remove parameters:

$$\mu_I^E \text{ (estimated value = 0.2 vs true value = 1.8 cell}^{-1} \text{ day}^{-1}, \text{ RSE = 61\%),}$$

$$\mu_L^E \text{ (estimated value = 0.3 vs true value = 3.6 cell}^{-1} \text{ day}^{-1}, \text{ RSE = 17\%), and}$$

$$\mu_I \text{ (estimated value = 0.013 vs true value = 0.055 day}^{-1}, \text{ RSE = 9\%).}$$

Details of the procedure are explained in Sections 4.5, 4.6, A2 and Table A2.

All removed parameters are related to death rates, of late effector cells (μ_L^E) and of the immunogen (μ_I, μ_I^E). In each case, the model still accounts for




Fig. 2. Schematic CD8 T cell differentiation diagram following immunization. **(A)** Schematic representation of System (1). **(B)** Schematic representation of System (2). Dashed black lines represent individual-dependent parameters, while straight black lines (only in **(B)**) represent parameters fixed within the population. Grey round-ended dotted lines represent feedback functions (see systems of equations).

death of late effector cells and of the immunogen, via parameters μ_L^L and μ_I^L . Nonlinear mixed effects models avoid redundancy in the description of biological processes, thus they allow reliable parameter estimation using synthetic data.

This leads to a reduction of the initial 12-parameters System (3) to the 9-parameters System (1),

$$\begin{cases} \dot{N} = -\mu_N N - \delta_{NE} IN, \\ \dot{E} = \delta_{NE} IN + \rho_E IE - [\mu_E E + \delta_{EL}] E, \\ \dot{L} = \delta_{EL} E - [\mu_L L + \delta_{LM}] L, \\ \dot{M} = \delta_{LM} L, \\ \dot{I} = [\rho_I I - \mu_I L] I. \end{cases} \quad (1)$$

where all parameters still account for individual variability (drawn from probability distributions). For the sake of simplicity the parameters are renamed in System (1): $\mu_L^L = \mu_L$ and $\mu_I^L = \mu_I$. Figure 2A displays a schematic representation of System (1).

2.2. A model of CD8 T cell dynamics accounting for in vivo inter-individual heterogeneity

Biological data from VV data set 1 (see Section 4.2 and Table 1) are confronted to System (1). Parameter estimation is performed using the SAEM algorithm [30] and, following the procedure described in Section 4.7, leads to further reduction of the model. Using *in vivo* data to estimate parameter values provides a priori less information than synthetic data: there are 59 individuals instead of 100 for synthetic data, and at most 15 measurements (15 individuals) at each time point are available whereas almost all measurements are available for the 100 individuals in synthetic data. Hence, it might be necessary to simplify the model to ensure correct parameter estimations, either mean values or random effects, similarly to what has been done in the previous section.

The first step in the model reduction procedure leads to an estimated value of parameter μ_L close to zero ($2 \times 10^{-8} \text{ cell}^{-1} \text{ day}^{-1}$), with a RSE > 100%, see Table 2, *Step 1*. Hence parameter μ_L is removed, and the estimation is performed again with the updated model. We observe that all mean value parameters have now RSE < 30%, so we conclude that their estimations are reliable (Table 2, *Step 2*).

In the second step of the procedure however, several random effects have large RSE and high shrinkages (Table 2, *Step 2* to *Step 5*). The shrinkage is defined in (5) as a measure of the difference between the estimated variance of a parameter and the empirical variance of its random effect. Parameter δ_{LM} has the worst RSE and the largest shrinkage (99%), so we remove the random effect of δ_{LM} . Estimating parameter values with the updated reduced model leads to removing successively random effects of δ_{EL} (RSE = 138%, shrinkage = 95%), ρ_E (shrinkage = 97%), and μ_N (shrinkage = 84%). At each step, RSE of mean value parameters are low, and quality of individual fits is preserved.

The resulting model, System (2) (see Figure 2B), comprises 8 parameters, 4 of them vary within the population (δ_{NE} , μ_E , ρ_I , μ_I) and 4 are fixed within the population (μ_N , ρ_E , δ_{EL} , δ_{LM}):

$$\begin{cases} \dot{N} = -\bar{\mu}_N N - \delta_{NE} IN, \\ \dot{E} = \delta_{NE} IN + [\bar{\rho}_E I - \mu_E E - \bar{\delta}_{EL}] E, \\ \dot{L} = \bar{\delta}_{EL} E - \bar{\delta}_{LM} L, \\ \dot{M} = \bar{\delta}_{LM} L, \\ \dot{I} = [\rho_I I - \mu_I L] I. \end{cases} \quad (2)$$

266
267
268
269
270

271
272
273
274
275

276
277

278
279
280
281
282
283
284
285
286
287
288
289
290
291
292

293
294
295
296
297
298
299
300

301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318

Table 2

Steps in estimating parameter values using VV data set 1 and System (1). The procedure is detailed in Section 4.7. At *Step 1*, the procedure leads to removing parameter μ_L . At *Step 2*, the random effect of δ_{LM} is removed. At *Step 3*, the random effect of δ_{EL} is removed. At *Step 4*, the random effect of ρ_E is removed. At *Step 5*, the random effect of μ_N is removed. At *Step 6*, no other action is required. Values used to take a decision are highlighted in bold at each step. In the first column, ‘m.v.’ stands for mean value, RSE is defined in (4), ‘r.e.’ stands for random effect, and the shrinkage is defined in (5). Note that values (mean values and random effects) of parameters μ_E , μ_L , and μ_I have to be multiplied by 10^{-6} (for μ_E and μ_L) and 10^{-5} (for μ_I). Units are omitted for the sake of clarity

	μ_N	δ_{NE}	ρ_E	μ_E	δ_{EL}	μ_L	δ_{LM}	ρ_I	μ_I
<i>Step 1</i>									
m.v.	0.59	0.002	0.9	5.2	0.13	0.02	0.09	0.08	1.9
RSE	5	30	2	21	11	207	8	7	28
r.e.	0.16	0.8	0.04	0.67	0.1	1.9	0.05	0.2	1.3
RSE	66	36	44	35	567	220	10^3	25	18
shrinkage	82	76	97	77	98	99	100	62	45
<i>Step 2</i>									
m.v.	0.60	0.003	0.9	4.8	0.12	-	0.10	0.09	2.3
RSE	5	29	3	21	10	-	8	6	25
r.e.	0.15	0.8	0.06	0.73	0.2	-	0.05	0.2	1.2
RSE	69	34	71	29	150	-	10^3	25	17
shrinkage	83	78	94	74	96	-	99	64	47
<i>Step 3</i>									
m.v.	0.60	0.001	1.00	5.0	0.12	-	0.10	0.08	2.0
RSE	5	32	1	20	10	-	8	7	29
r.e.	0.16	0.8	0.04	0.67	0.2	-	-	0.2	1.3
RSE	55	35	20	31	138	-	-	25	18
shrinkage	81	75	98	77	95	-	-	63	45
<i>Step 4</i>									
m.v.	0.59	0.002	0.9	5.2	0.12	-	0.10	0.09	2.1
RSE	5	29	2	20	11	-	8	6	24
r.e.	0.12	0.9	0.04	0.74	-	-	-	0.2	1.2
RSE	102	32	47	29	-	-	-	24	16
shrinkage	89	75	97	72	-	-	-	63	49
<i>Step 5</i>									
m.v.	0.59	0.004	0.8	4.5	0.12	-	0.10	0.09	2.7
RSE	5	32	4	21	11	-	8	6	21
r.e.	0.15	0.8	-	0.85	-	-	-	0.2	1.0
RSE	72	32	-	24	-	-	-	23	16
shrinkage	84	73	-	65	-	-	-	61	57
<i>Step 6</i>									
m.v.	0.60	0.001	1.0	5.3	0.12	-	0.10	0.08	1.9
RSE	5	29	0	20	11	-	8	7	27
r.e.	-	0.9	-	0.69	-	-	-	0.2	1.3
RSE	-	29	-	28	-	-	-	23	17
shrinkage	-	72	-	75	-	-	-	62	46


Bars highlight fixed parameters within the population. This system enables to describe VV data set 1 and its inter-individual variability (see Figure 3). The inter-individual variability is entirely contained in the activation rate of naive cells (δ_{NE}), the mortality-induced regulation of effector cells (μ_E), and the dynamics of the immunogen (ρ_I and μ_I).

Figure 3A shows the good agreement between model predictions and individual measurements for each CD8 T cell subpopulation. Model predictions are obtained from numerical simulations of System (2) performed with estimated individual parameter values. Despite over- or under-estimation of some individual observations, the 90th percentile

of the difference between observed and predicted values (dashed line) shows that most experimental cell counts are efficiently predicted (estimated errors are relatively small for all subpopulations: $a_N = a_M = 0.3 \log_{10}(\text{cells})$, $a_E = a_L = 0.4 \log_{10}(\text{cells})$). Parameter values are given in Table 3.

Figure 4 shows the estimated dynamics of early- and late-effector and memory cells of two individuals. One individual (Figure 4A) was monitored on days 7, 15 and 47pi leading to three measurements points for late effector cells and two for early effector and memory cells. Despite missing measurements (memory cell counts on D7pi, and early effector cell counts on D47pi), estimated dynamics are in agreement with

(A) VV - Observation vs prediction



(B) VV - Individual dynamics




Fig. 3. Experimental and simulated individual cell counts for VV data set 1 (logarithmic scale). (A) Observed vs predicted values. For each CD8 T cell count experimental point, the prediction is obtained by simulating System (2). Naive (blue), early effector (red), late effector (green), and memory (purple) cell counts are depicted. Dashed lines represent the 90th percentile of the difference between observed and predicted values, and the solid black line is the curve $y = x$. (B) Naive (upper left, blue), early effector (upper right, red), late effector (lower left, green) and memory (lower right, purple) cell counts up to D47pi. Experimental measurements are represented by colored dots (same color code), simulated individual trajectories by grey lines, and the average population dynamics by a straight colored line (same color code).

348 what is expected, especially regarding the time and
 349 height of the peak of the response and the following
 350 contraction phase. The other individual (Figure 4B)
 351 had cell count measurements only on day 8pi, yet the
 352 estimated dynamics correspond to an expected behav-

ior. This could not have been obtained by fitting this
 individual alone. Hence we are able to simulate likely
 dynamics even with a small amount of data points and
 missing cell count measurements at some time points,
 thanks to the use of nonlinear mixed effects models

353
 354
 355
 356
 357

Table 3

Estimated parameter values for VV and Tumor data sets 1 (median of log-normal distribution for parameters with random effects, RSE (%) in parentheses), obtained with System (2), and estimated parameter values from [10] (VV immunization). Estimations have been performed independently

Parameters	Units	Estimated Values (RSE%)				Values from Crauste et al. [10]
		VV data set 1		Tumor data set 1		
<i>Parameters fixed within the population</i>						
$\bar{\mu}_N$	day ⁻¹	0.60	(5)	0.32	(15)	0.75
$\bar{\rho}_E$	day ⁻¹	1.02	(0)	0.43	(4)	0.64
$\bar{\delta}_{EL}$	day ⁻¹	0.12	(9)	0.10	(3)	0.59
$\bar{\delta}_{LM}$	day ⁻¹	0.10	(8)	0.07	(14)	0.03
<i>Parameters varying within the population</i>						
δ_{NE}	day ⁻¹	0.001	(29)	0.063	(22)	0.009
$\omega_{\delta_{NE}}$	day ⁻¹	0.9	(29)	0.4	(54)	-
μ_E	10 ⁻⁶ cell ⁻¹ day ⁻¹	5.3	(20)	4.9	(18)	21.5
ω_{μ_E}	10 ⁻⁶ cell ⁻¹ day ⁻¹	0.7	(28)	0.2	(78)	-
ρ_I	day ⁻¹	0.08	(6)	0.11	(3)	0.64
ω_{ρ_I}	day ⁻¹	0.23	(23)	0.06	(58)	-
μ_I	10 ⁻⁵ cell ⁻¹ day ⁻¹	1.9	(26)	2.4	(18)	1.8
ω_{μ_I}	10 ⁻⁵ cell ⁻¹ day ⁻¹	1.3	(17)	0.6	(22)	-
<i>Residual errors</i>						
a_N	cell counts (log10)	0.3	(15)	0.5	(14)	-
a_E	cell counts (log10)	0.4	(10)	0.5	(9)	-
a_L	cell counts (log10)	0.4	(9)	0.6	(8)	-
a_M	cell counts (log10)	0.3	(10)	0.5	(10)	-

and the parameter estimation procedure. By focusing first on the population dynamics (based on a collection of individual dynamics), the method enables to recover the whole individual dynamics. This is a huge advantage when data sampling frequency is low.

Similar good results are obtained for Tumor data set 1 (see Figure 5 and parameter values in Table 3). Therefore System (2) enables to describe inter-individual variability in different immunization contexts, here VV and Tumor immunizations, and with only few data points per individual.

Estimated parameter values obtained with System (2) for VV or Tumor data sets are in the same range as in the estimation previously performed on average cell counts on a similar experimental set (VV immunization [10]), see Table 3. Some differences are observed for estimated values of differentiation rates, yet for the 3 estimations (VV data set 1, Tumor data set 1, [10]) parameter values remain in the same order of magnitude, indicating consistency between the two studies. Estimated values of parameter δ_{NE} show the largest relative differences. Yet, the largest difference is observed between VV and Tumor data sets obtained with System (2), rather than between these values and the one obtained in [10]. This may highlight a potential difference in the capacity of the two immunogens (VV and Tumor) to activate naive cells. This is investigated in the next section.

2.3. Immunization-dependent parameters

Parameter comparison between immunizations. VV and Tumor induced immunizations differ in many aspects. VV immunizations are virus-mediated, use the respiratory tract to infect cells, and trigger an important innate response. Tumor immunizations involve eukaryotic cells bearing the same antigen, use subcutaneous routes, and induce a reduced innate response.

From the independent estimations on VV and Tumor data sets (Table 3), we compute differences between estimated values of fixed effects. Differences are large for parameters – in decreasing order – δ_{NE} (62%), $\bar{\rho}_E$ (60%), $\bar{\mu}_N$ (47%), ρ_I (37%), and $\bar{\delta}_{LM}$ (30%). These large differences may result from biological processes involved in the CD8 T cell response that differ depending on the immunogen.

Consequently, combining both data sets (VV and Tumor) as observations may highlight which parameters have to be significantly different to describe both data sets.

Parameters depending on immunization. To perform this analysis, we combine VV and Tumor data sets 1 and we include a categorical covariate into the model to estimate parameter values (see Section 4.5). Covariates allow to identify parameter values that are




Fig. 4. The dynamics of three subpopulations (early effector - red, late effector - green, memory - purple) are simulated with System (2) for two individuals. Experimental measurements are represented by dots, simulations of the model by straight lines. (A) Individual cell counts have been measured on days 7, 15 and 47pi. (B) Individual cell counts have been measured on day 8pi only. Although each individual is not characterized by enough experimental measurements to allow parameter estimation on single individuals, nonlinear mixed effects models provide individual fits by considering a population approach.

significantly different between two CD8 activation conditions (tumors *vs* virus).

A covariate is added to the fixed effects of the five parameters that showed the larger differences in the initial estimation: δ_{NE} , $\bar{\rho}_E$, $\bar{\mu}_N$, ρ_I and $\bar{\delta}_{LM}$. This results in the estimation of two different parameter values for parameters $\bar{\rho}_E$, $\bar{\mu}_N$ and $\bar{\delta}_{LM}$ (that are fixed within the population) and two probability distributions with different mean values for parameters δ_{NE} and ρ_I (that vary within the population).

One may note that adding a covariate increases the number of parameters to estimate. However, the number of parameters is not doubled, since we assumed that parameters without covariates are shared by both immunization groups. In addition, the data set is larger, since it combines VV and Tumor measure-

ments. Hence the number of parameters with respect to the amount of data remains reasonable.

From this new estimation, we conclude that among the five selected parameters the covariates of only four of them are significantly different from zero: δ_{NE} , $\bar{\rho}_E$, $\bar{\mu}_N$, and $\bar{\delta}_{LM}$ (Wald test, see Section 4.5). The estimation is therefore performed a second time assuming ρ_I distribution is the same in both groups. Then the Wald test indicates that the remaining covariates are significantly different from zero (Table 4).


Figure 6 shows the estimated distribution for parameter δ_{NE} that varies within the population and for which we included a covariate. Histograms display the estimated individual parameter values of δ_{NE} . They show two distinct distributions of δ_{NE} values, corresponding to VV (red)- and Tumor (green)-associated values. The histograms and the theoretical distributions are in agreement.

Table 4 gives the estimated values of all parameters in both groups. Regarding parameters that do not vary within the population, it is required for parameters $\bar{\mu}_N$, $\bar{\delta}_{LM}$ and $\bar{\rho}_E$ to be different to describe each data set, and this difference is accounted for with a covariate parameter. Noticeably, using categorical covariates mostly improves the confidence in the estimation, as highlighted by either RSE values in the same range ($\bar{\mu}_N$, $\bar{\rho}_E$) or improved (all other parameters) RSE values (Tables 3 and 4).

In summary, we identified parameters whose values are significantly different according to the immunogen used to activate CD8 T cells. These parameters correspond to the dynamics of naive cells ($\bar{\mu}_N$), their activation (δ_{NE}), the proliferation of early effector cells ($\bar{\rho}_E$), and differentiation to memory cells ($\bar{\delta}_{LM}$). We hence conclude that different immunizations affect the CD8 T cell activation process in the first phase of the response (priming, activation of naive cells, expansion of the CD8 T cell population) as well as the development of the memory population. Different immunizations also induce various degrees of variability in the responses through the activation of naive cells, and our mathematical approach quantitatively estimates these degrees of variability.

2.4. Predicting dynamics following VV and Tumor immunizations

To challenge System (2) and the estimated parameters (Table 4), we compare simulated outputs to an additional data set, not used for data fitting, of both

(A) Tumor - Observation *vs* prediction

(B) Tumor - Individual dynamics




Fig. 5. Experimental and simulated individual cell counts for Tumor data set 1 (logarithmic scale). (A) Observed *vs* predicted values. For each CD8 T cell count experimental point, the prediction is obtained by simulating System (2). Naive (blue), early effector (red), late effector (green), and memory (purple) cell counts are depicted. Dashed lines represent the 90th percentile of the difference between observed and predicted values, and the solid black line is the curve $y = x$. (B) Naive (upper left, blue), early effector (upper right, red), late effector (lower left, green) and memory (lower right, purple) cell counts up to D47pi. Experimental measurements are represented by colored dots (same color code), simulated individual trajectories by grey lines, and the average population dynamics by a straight colored line (same color code).

478
479
480
481
482
483

VV and Tumor immunizations, VV data set 2 and Tumor data set 2 (Table 1 and Section 4.8).

We already know the probability distribution of parameters (Table 4), so we only estimate individual parameters in order to fit individual dynamics. Results are shown in Figure 7, for both VV and Tumor

data sets 2. Individual fits are available in Section A3. It is clear that estimated individual dynamics are consistent with previous individual dynamics estimations. Hence, we validate System (2) and values estimated in both VV and Tumor immunization contexts by showing that estimated parameter values

484
485
486
487
488
489

Table 4

Estimated parameter values using combined VV and Tumor data sets 1. Parameters that do not vary within the population are shown in the upper part of the table, whereas individual-dependent parameters are shown in the central part (mean and standard deviation values). RSE (%) are indicated in parentheses. Parameters whose values depend on the immunogen (VV, Tumor) are highlighted in grey, and the p -value characterizing the covariate non-zero value is shown in the last column

Parameters	Units	VV	(RSE%)	Tumor	(RSE%)	p -value
<i>Parameters fixed within the population</i>						
$\bar{\mu}_N$	day ⁻¹	0.59	(7)	0.34	(24)	10 ⁻⁵
$\bar{\rho}_E$	day ⁻¹	0.69	(2)	0.46	(17)	10 ⁻⁹
$\bar{\delta}_{EL}$	day ⁻¹	0.11	(4)	0.11	(4)	-
$\bar{\delta}_{LM}$	day ⁻¹	0.10	(10)	0.07	(10)	0.01
<i>Parameters varying within the population</i>						
δ_{NE}	day ⁻¹	0.006	(24)	0.047	(17)	10 ⁻⁹
$\omega_{\delta_{NE}}$	day ⁻¹	0.6	(31)	0.6	(31)	-
μ_E	10 ⁻⁶ cell ⁻¹ day ⁻¹	4.1	(17)	4.1	(17)	-
ω_{μ_E}	10 ⁻⁶ cell ⁻¹ day ⁻¹	0.7	(26)	0.7	(26)	-
ρ_I	day ⁻¹	0.1	(3)	0.1	(3)	-
ω_{ρ_I}	day ⁻¹	0.1	(17)	0.1	(17)	-
μ_I	10 ⁻⁵ cell ⁻¹ day ⁻¹	2.9	(18)	2.9	(18)	-
ω_{μ_I}	10 ⁻⁵ cell ⁻¹ day ⁻¹	0.9	(15)	0.9	(15)	-
<i>Residual errors</i>						
a_N	cell counts (log10)	0.5	(10)	0.5	(10)	-
a_E	cell counts (log10)	0.5	(7)	0.5	(7)	-
a_L	cell counts (log10)	0.5	(6)	0.5	(6)	-
a_M	cell counts (log10)	0.4	(8)	0.4	(8)	-




Fig. 6. Probability distribution of parameter δ_{NE} defined with a covariate. Estimated distributions of VV-associated (left, red) and Tumor-associated (right, green) values are plotted. Histograms of estimated individual parameter values are also plotted (red for VV-associated values, green for Tumor-associated values).

allow to characterize individual CD8 T cell counts obtained in similar contexts (Figure 7 and Section A3).

3. Discussion

When following an *in vivo* immune response, experimental measurements are often limited by

either ethical issues or tissue accessibility. Consequently, one often ends up measuring cell counts in peripheral blood on a restricted number of time points per individual, over the duration of a response (see Figure 4). Among measurements of a single individual, cell counts are often missing for one or more cell subpopulations. With such data, estimation of all model parameters becomes unlikely. Using nonlinear mixed effects models, we propose a dynamical model of CD8 T cell dynamics that circumvents this difficulty by assuming that all individuals within a population share the main characteristics. Using this framework, we propose an accurate description of individual dynamics, even though individual measurements are scarce. Indeed, we are able to obtain both good fits and relevant dynamics for individuals with only few cell count measurements, as illustrated in Figure 4. These results indicate that knowledge of population dynamics parameters and numerical simulations complement information given by experimental measurements.

Starting from the model described in Crauste et al. [10] that could efficiently describe CD8 T cell dynamics, at the level of average population cell-counts in peripheral blood, we built and validated this nonlinear mixed effects model in a step-wise fashion. The system was first modified to ensure correct parameter estimation when confronted to ideal, highly informative data. In a second step, the model was again

496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524




Fig. 7. Observed vs estimated values of individual CD8 T cell counts for (A) VV data set 2 and (B) Tumor data set 2. Individual parameter values have been estimated with System (2) and population parameter values and distributions previously defined on VV and Tumor data set 1. In both figures, naive (blue), early effector (red), late effector (green), and memory (purple) cell counts are depicted. Grey points correspond to individual values from Figure 3A and Figure 5A. The black straight line is $y = x$.

modified and parameter values estimated by using experimental measurements generated through a VV immunization. We next identified parameters – hence biological processes – that vary between individuals and explain the between-individual variability, and other parameters that can be fixed within the population to explain biological data (measured in VV and Tumor immunization contexts). Finally, by including a categorical covariate we additionally identified immunization-dependent parameters.

In order to determine the contribution of each parameter to inter-individual variability, one could

argue that performing a sensitivity analysis would shed light on the more sensitive parameters. Even though model's output sensitivity to parameters and contribution of each parameter to individual variability may be partly related, they are nonetheless different concepts. Sensitivity analysis would highlight the influence of a parameter on the population dynamics, whereas our objective is to reproduce several individual outputs (individual dynamics) which exhibit more or less variability than the average population behavior. Therefore the use of classical tools like Sobol indices [31] or generalized sensitivity functions [32] is not adapted to handle the current question. Hence, we proposed a procedure, based on estimated errors and the shrinkage, to identify a minimal set of parameters (fixed and random effects) required to describe the data sets. It can be noticed that the shrinkage, expressed as a ratio of variances (see (5)), provides an information similar to the one given by Sobol indices.

Noteworthy, from a biological point of view, the removal of one parameter during model reduction (for example, the death rate of late effector cells) must not be understood as if the corresponding process is not biologically meaningful. Rather, based on the available data, our methodology found that some processes are non-necessary in comparison with the ones described by the system's equations.

Similarly, parameters characterizing immunogen dynamics vary within the population whereas model reduction led to remove the variability of equivalent processes (proliferation for instance) in CD8 T cell dynamics. It is likely that this is due to a lack of experimental measures on immunogen dynamics (whether virus load evolution or tumor growth), and one cannot conclude that inter-individual variability mostly comes from immunogen dynamics. Information on immunogen dynamics, when available, could significantly improve parameter estimation and help refining the information on inter-individual variability during CD8 T cell responses.

In our biological data, inter-individual variability is explained only by variability in the activation rate of naive cells, the mortality rate of effector cells, and dynamics (proliferation and death) of the immunogen. The former is actually in good agreement with the demonstration that in diverse infection conditions the magnitude of antigen-specific CD8 T cell responses is primarily controlled by clonal expansion [33].

Two of the three differentiation rates (early effector cell differentiation in late effector cells, and late

537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588




Fig. 8. Positive side-effect of using covariates. For two illustrative individuals, accounting for covariates allows to better estimate early effector cell dynamics: red plain curve with covariate, blue dashed curve without covariate.

effector cell differentiation in memory cells) do not need to vary to describe our data sets. This robustness of the differentiation rates is in good agreement with the auto-pilot model that shows that once naive CD8 T cells are activated their differentiation in memory cells is a steady process [34, 35].

Eventually, using nonlinear mixed effects models and an appropriate parameter estimation procedure, we were able to quantitatively reproduce inter-individual variability in two different immunization contexts (VV and Tumor) and provide predictive population dynamics when confronted to another data set (for both immunogens). This demonstrates the robustness of the model.

The addition of a categorical covariate allowed us to identify parameters that are immunization-dependent. Interestingly they control the activation of the response (priming, differentiation of naive cells, expansion of effector cells) as well as the generation of memory cells. This is again in good agreement with the biological differences that characterize the two immunogens used in this study. Indeed, pathogen-associated molecular patterns (PAMP) associated with vaccinia virus will activate a strong innate immune response that will provide costimulatory signals that in turn will increase the efficiency of naive CD8 T cell activation [5]. In contrast, when primed by tumor cells CD8 T cells will have access to limited amounts of costimulation derived from damage associated molecular patterns [36]. The amount of costimulation will also control the generation of memory cells [37]. Focusing on average CD8 T cell behaviors (not shown) highlights stronger responses following VV immunization, characterized by a faster differentiation of naive cells and a higher peak of the response (at approximately 3×10^5 cells compared to 10^5 cells for the Tumor

induced response). Also, in average, more memory cells are produced following VV immunization. Hence the addition of covariates to the model parameters has allowed to identify biologically relevant, immunogen-dependent parameters.

Using covariates has additional advantages. First, they allow to consider a larger data set (in our case, the combination of two data sets) without adding too many parameters to estimate (4 covariates in our case). This is particularly adapted to situations where only some parameters are expected to differ depending on the data set (here, the immunogen). Second, and as a consequence, model fits may be improved compared to the situation where data sets generated with different immunogens are independently used to estimate parameters. Figure 8 illustrates this aspect: dynamics of two individuals are displayed, with and without covariate. In both cases using the covariate (and thus a larger data set) improved the quality of individual fits, and in the case of Individual 1 generated more relevant dynamics with a peak of the response occurring earlier, before day 10pi. No individual fit has been deteriorated by the use of a covariate (not shown).

Finally, CD8 T cell response dynamics to both VV and Tumor immunogens were well captured for data sets that had not been used to perform parameter estimation (Section 2.4). The behavior of each individual was estimated with the prior knowledge acquired on the population (i.e. fixed parameter values and variable parameter distributions) and proved consistent with previous estimated individual behaviors. The correct prediction of individual behaviors by the model, in a simple mice experiment, paves the way to personalized medicine based on numerical simulations. Indeed, once the population parameters are defined, numerical simulation of individuals can be

performed from a few measurements per individual and consequently would allow to adapt personalized therapies.

4. Material, methods and models

4.1. Ethics statement

CECCAPP (Lyon, France) approved this research accredited by French Research Ministry under project #00565.01.

Mice were anesthetized either briefly by placement in a 3% isoflurane containing respiratory chamber or deeply by intraperitoneal injection of a mix of Ketamin (70 mg/kg) and Xylazin (9 mg/kg). All animals were culled by physical cervical disruption.

4.2. Data

All data used in this manuscript are available at https://osf.io/unkpt/?view_only=ff91bd89bc32421dbcb356c3509ca55.

Experimental Models. C57BL/6 mice (C57BL6/J) and CD45.1+ C57BL/6 mice (B6.SJL-Ptpr^aPepr^b/BoyCr1) were purchased from CRL. F5 TCR-tg mice recognizing the NP68 epitope were crossed to a CD45.1+ C57BL/6 background (B6.SJL-Ptpr^aPepr^b/BoyCr1-Tg(CD2-TcrF5,CD2-TcrBF5)1Kio/Jmar) [38]. They have been crossed at least 13 times on the C57BL6/J background. All mice were homozygous adult 6-8-week-old at the beginning of experiments. They were healthy and housed in our institute's animal facility under Specific Pathogen-Free conditions.

Age- and sex-matched litter mates or provider's delivery groups, which were naive of any experimental manipulation, were randomly assigned to 4 experimental groups (of 5 mice each) and co-housed at least for one week prior to experimentation. Animals were maintained in ventilated enriched cages at constant temperature and hygrometry with 13hr/11hr light/dark cycles and constant access to 21 kGy-irradiated food and acid (pH = 3 ± 0.5) water.

Vaccinia Virus (VV) Immunization. 2 × 10⁵ naive CD8 T cells from CD45.1+ F5 mice were transferred by retro-orbital injection in 59, 6-8-week-old, congenic CD45.2+ C57BL/6 mice briefly anaesthetized

with 3% isoflurane. The day after deeply Xylazin/Ketamin-anaesthetized recipient mice were inoculated intra-nasally with 2 × 10⁵ pfu of a vaccinia virus expressing the NP68 epitope (VV-NP68) provided by Pr. A.J. McMichael [38].

Tumor Immunization. 2 × 10⁵ naive CD8 T cells from CD45.1+ F5 mice were transferred by retro-orbital injection in 55, 6-8-week-old, congenic CD45.2+ C57BL/6 mice briefly anaesthetized with 3% isoflurane. The day after, recipients were subcutaneously inoculated with 2.5 × 10⁶ EL4 lymphoma cells expressing the NP68 epitope (EL4-NP68) provided by Dr. T.N.M. Schumacher [39].

Phenotypic Analyses. Mice were bled at intervals of at least 7 days. Blood cell suspensions were cleared of erythrocytes by incubation in ACK lysis solution (TFS). Cells were then incubated with efluor780-coupled Fixable Viability Dye (eBioscience) to label dead cells. All surface stainings were then performed for 45 minutes at 4°C in PBS (TFS) supplemented with 1% FBS (BioWest) and 0.09% NaN₃ (Sigma-Aldrich). Cells were fixed and permeabilized with the Foxp3-fixation and permeabilization kit (eBioscience) before intra-cellular staining for one hour to overnight. The following mAbs(clones) were utilized: Bcl2(BCL/10C4), CD45.1(A20) and CD45(30-F11) from Biolegend, Mki67(SolA15) and CD8(53.6.7) from eBioscience, and CD44 (IM7.8.1) from Miltenyi. Samples were acquired on a FACS LSR Fortessa (BD biosciences) and analyzed with FlowJo software (TreeStar).

CD8 T Cell Differentiation Stages. For both immunizations (VV and Tumor), phenotypic cell subsets based on Mki67-Bcl2 characterization [10] have been identified and the corresponding cell counts measured in blood, from day 4 post-inoculation (pi) up to day 47pi (VV and Tumor data sets 1, Table 1). Naive cells are defined as CD44-Mki67-Bcl2+ cells, early effector cells as CD44+Mki67+Bcl2- cells, late effector cells as CD44+Mki67-Bcl2- cells, and memory cells as CD44+Mki67-Bcl2+ cells [10].

4.3. Models of CD8 T cell dynamics

Initial model. The following system (3) is made of ODE and describes individual behaviors. This is the model in [10], it describes CD8 T cell subpopulation dynamics (see Section 4.2, Paragraph CD8 T Cell Differentiation Stages) as well as the immunogen

load dynamics in primary immune responses, as follows

$$\begin{cases} \dot{N} = -\mu_N N - \delta_{NE} IN, \\ \dot{E} = \delta_{NE} IN + \rho_E IE - [\mu_E E + \delta_{EL}] E, \\ \dot{L} = \delta_{EL} E - [\mu_L^L L + \mu_L^E E + \delta_{LM}] L, \\ \dot{M} = \delta_{LM} L, \\ \dot{I} = [\rho_I I - \mu_I^E E - \mu_I^L L - \mu_I] I. \end{cases} \quad (3)$$

The variables N , E , L and M denote the four CD8 T cell subpopulation counts, naive, early effector, late effector, and memory cells respectively (see Section 4.2), and I is the immunogen load. For details regarding the construction and validation of this model we refer the readers to [10]. We hereafter briefly discuss this model.

The immunogen load dynamics are normalized with respect to the initial amount [10, 40], so $I(0) = 1$. The initial amounts of CD8 T cell counts are $N(0) = 10^4$ cells, $E(0) = 0$, $L(0) = 0$ and $M(0) = 0$.

Parameters δ_k are the differentiation rates, with $k = NE, EL$ or LM for differentiation from naive to early effector cells, from early effector to late effector cells and from late effector to memory cells, respectively.

Death parameters are denoted by μ_k , where $k = N, E$ and I for the death of naive cells, early effector cells and the immunogen respectively. Notations μ_X^Y for some mortality-related parameters refer to parameters μ_{XY} in [10]: the subscript X refers to the CD8 T cell population or the immunogen that dies, and the superscript Y to the CD8 T cell population responsible for inducing death.

Early and late effector cells are cytotoxic, GrzB+ cells [10], so due to competition for limited resources (such as cytokines) and fratricidal death [41, 42] we assumed fratricide killing by CD8 T cells. Consequently the model accounts for effector-cell regulated death rates of both effector cells and the immunogen [10, 40]. Natural mortality rates are considered for naive and memory cells (μ_N, μ_I).

Proliferation parameters of early effector cells and the immunogen are respectively denoted by ρ_E and ρ_I . Proliferation of both CD8 T cells and the immunogen are partially controlled by the immunogen, so proliferation rates are assumed to depend on I . Noticeably, among CD8 T cells only early effec-

tor cells are Mki67+ cells so they are the only cells assumed to proliferate and divide [10].

System (3) has been introduced and validated on a similar VV data set in [10]. To account for individual behavior, parameters will be complexified assuming they are drawn from probability distributions and in the same time this system will be simplified through a model selection procedure to ensure the correct estimation of parameter values with available data sets (see Sections 4.6 and 4.7).

Model selected on synthetic data. Model (3) has been obtained by fitting average dynamics of a CD8 T cell immune response [10]. When confronting this model to heterogeneous data of individual CD8 T cell dynamics and using mixed effects modeling, it is mandatory to verify that assumptions of the mixed effects model (see Section 4.4) are valid. To investigate this mathematical property, we will rely on synthetic data that are highly informative compared to experimental data and, additionally, for which we know the parameter values behind data generation so we possess an explicit control on parameter estimations. Using synthetic data and the procedure described in Section 4.6 leads to the selection of the System (1),

$$\begin{cases} \dot{N} = -\mu_N N - \delta_{NE} IN, \\ \dot{E} = \delta_{NE} IN + [\rho_E IE - \mu_E E - \delta_{EL}] E, \\ \dot{L} = \delta_{EL} E - [\mu_L L + \delta_{LM}] L, \\ \dot{M} = \delta_{LM} L, \\ \dot{I} = [\rho_I I - \mu_I L] I. \end{cases}$$

This model is dynamically similar to System (3), but in order to correctly fit synthetic data and to satisfy the assumptions of mixed effects modeling, parameters μ_L^E , μ_I^E and μ_I have been removed: it was not possible to accurately estimate them to non-zero true values. For the sake of simplicity the parameters are renamed in System (1): $\mu_L^L = \mu_L$ and $\mu_I^L = \mu_I$. System (1) is defined by 9 parameters.

Model selected on biological data. When using biological, *in vivo* experimental data instead of synthetic data, not as many measurements per individual can be obtained (see Table 1) so the dynamical model may easily be over-informed (too many parameters compared to the size of the sampling). Using System (1), the confrontation with VV data set 1 leads to the modified System (2),

$$\begin{cases} \dot{N} = -\bar{\mu}_N N - \delta_{NE} I N, \\ \dot{E} = \delta_{NE} I N + [\bar{\rho}_E I E - \mu_E E - \bar{\delta}_{EL}] E, \\ \dot{L} = \bar{\delta}_{EL} E - \bar{\delta}_{LM} L, \\ \dot{M} = \bar{\delta}_{LM} L, \\ \dot{I} = [\rho_I I - \mu_I L] I. \end{cases}$$

812 System (2) has 8 parameters (μ_L has been removed
813 from System (1)): 4 parameters are fixed within the
814 population ($\bar{\mu}_N, \bar{\rho}_E, \bar{\delta}_{EL}, \bar{\delta}_{LM}$) and 4 parameters have
815 a random effect ($\delta_{NE}, \mu_E, \rho_I, \mu_I^L$).

816 4.4. Nonlinear mixed effects models

817 Nonlinear mixed effects models allow a descrip-
818 tion of inter-individual heterogeneity within a
819 population of individuals (here, mice). The main
820 idea of the method is to consider that since all indi-
821 viduals belong to the same population they share
822 common characteristics. These common character-
823 istics are called “fixed effects” and characterize an
824 average behavior of the population. However, each
825 individual is unique and thus differs from the aver-
826 age behavior by a specific value called “random
827 effect”.

828 This section briefly describes our main hypotheses.
829 Details on the method can be found in [17–19, 43].

830 Each data set $\{y_{i,j}, i = 1, \dots, N_{ind}, j = 1, \dots, n_i\}$
831 is assumed to satisfy

$$y_{i,j} = f(x_{i,j}, \psi_i) + a\varepsilon_{i,j},$$

832 where $y_{i,j}$ is the j^{th} observation of individual i , N_{ind}
833 is the number of individuals within the population and
834 n_i is the number of observations for the i^{th} individual.

835 The function f accounts for individual dynamics
836 generated by a mathematical model. In this work f
837 is associated with the solution of a system of ODE,
838 see Section 4.3. The function f depends on known
839 variables, denoted by $x_{i,j}$, and parameters of the i^{th}
840 individual, denoted by ψ_i .

841 Individual parameters ψ_i are assumed to be
842 split into fixed effects (population-dependent effects,
843 average behavior) and random effects (individual-
844 dependent effects). If ψ_i^k denotes the k -th parameter
845 characterizing individual i , then it is assumed that

$$\log(\psi_i^k) = \log(p_{pop}^k) + \eta_i^k,$$

846 where the vector of parameters $p_{pop} = (p_{pop}^k)_k$ mod-
847 els the average behavior of the population, and $\eta_i =$
848 $(\eta_i^k)_k$ represents how the individual i differs from this

849 average behavior. Variables $\eta_i^k \sim \mathcal{N}(0, \omega_k^2)$, and they
850 are assumed independent and identically distributed.
851 The variance ω_k^2 quantifies the variability of the k -
852 th parameter within the population. From now on
853 we will denote by ω^2 the vector of variances $(\omega_k^2)_k$.
854 Parameters ψ_i are assumed to follow a log-normal
855 distribution to ensure their positivity.

856 The residual errors, combining model approxima-
857 tions and measurement noise, are denoted by $a\varepsilon_{i,j}$.
858 They quantify how the model prediction is close to
859 the observation. Residual errors are assumed inde-
860 pendent, identically and normally distributed, *i.e.*
861 $\varepsilon_{i,j} \sim \mathcal{N}(0, 1)$. Moreover, the random effects η_i and
862 the residual errors $a\varepsilon_{i,j}$ are mutually independent. In
863 this work, we assume a *constant* error model, with a
864 constant a , for all cell populations, since they are all
865 observed in log10 scale. The error parameter is esti-
866 mated for each subpopulation (naive cells - a_N ; early
867 effector cells - a_E ; late effector cells - a_L ; memory
868 cells - a_M). When data on the immunogen dynam-
869 ics are available (only when using synthetic data),
870 we assume a proportional error for the immunogen
871 which is observed, so that $a_I = b_I f$.

872 We will write that a parameter is *fixed within the*
873 *population* if all individuals have the same value for
874 this parameter. On the contrary, if the variance ω_k^2
875 of a parameter is non-zero, then this parameter will
876 account for inter-individual variability within the
877 population.

878 4.5. Parameter estimation

879 Parameter values are estimated with the Stochastic
880 Approximation Expectation-Maximization (SAEM)
881 algorithm. This algorithm is adapted to nonlinear
882 mixed effects models [18] and has been shown
883 to quickly converge under general conditions [17].
884 Moreover, an implementation of the SAEM algorithm
885 is available in Monolix [30], a freely available soft-
886 ware that provides different indicators to quantify the
887 quality of estimations and fit. We used the SAEM
888 algorithm and Monolix in this work.

889 *Population and individual parameters.* Under the
890 previous assumptions (Section 4.4), cell population
891 dynamics (average behavior and inter-individual vari-
892 ability) are described by parameters: p_{pop}, ω^2 and a .
893 These parameters are estimated by maximizing the
894 likelihood with the SAEM algorithm.

895 Once these parameters have been estimated, each
896 individual vector of parameters ψ_i is estimated

by maximizing the conditional probabilities $\mathbb{P}(\psi_i | y_{i,j}; \hat{p}_{pop}, \hat{\omega}^2, \hat{a})$, where \hat{x} denotes the estimated value of x .

Both estimations are performed with Monolix software [30]. Files to run the algorithm (including all algorithm parameters) are available at <https://plmlab.math.cnrs.fr/audebert/cd8-responses>.

Covariates. In order to study whether differences observed in parameter values between VV and Tumor data sets (Table 1) are only related to random sampling or if they can be explained by the immunogen, we use categorical covariates (Section 2.3).

To tackle this question, we first pool together VV and Tumor data sets 1. Second, using this full data set, we estimate parameter values by assuming that fixed effects of some Tumor-associated parameters are different from those of the corresponding VV-associated parameters.

To introduce categorical covariates in our mixed effects model, we assume that if an individual is either in Tumor or VV data set then the probability distribution of its individual parameter vector ψ_i has a different mean. We write

$$\log(\psi_i^k) = \log(p_{pop}^k) + \beta^k c_i + \eta_i^k,$$

where c_i equals 0 if individual i is in VV data set 1 and 1 if it is in Tumor data set 1, and $\beta = (\beta^k)_k$ is a vector of covariate parameters. We test whether the estimated covariate parameter $\hat{\beta}$ is significantly different from zero with a Wald test, using Monolix software [30], and we use a p -value threshold at 0.05.

Parameters $(p_{pop}, \omega^2, a, \beta)$ are then characterizing cell population dynamics for both VV and Tumor immunogens. If the estimated vector $\hat{\beta}$ is significantly different from zero, then part of the experimentally observed variability could be explained by the immunogen.

4.6. Model selection on synthetic data

Model selection relies on criteria that allow to evaluate to which end a model appropriately satisfies *a priori* assumptions. For instance, one usually requires a model to correctly fit the data, and uses so-called quality of fit criteria, and/or requires that initial modeling assumptions are satisfied.

Here, we do not use quality of fit criteria to select a model because all models correctly fit data due to a priori over-informed models that have too many parameters compared to available data (see Paragraph

Model selection below). Instead, we focus on the capacity of the parameter estimation procedure to correctly estimate model parameters and to the a posteriori validation of statistical assumptions. To do so, we first use synthetic data (see Paragraph Generation of 551 synthetic data below). We take advantage of the fact that we know the exact parameter values used to generate synthetic data, so in order to evaluate the correctness of estimated parameter values we rely on:

- the relative difference between the estimated parameter value and the true value,
- the relative standard error (RSE), defined as the ratio between the standard error (square root of the diagonal elements of the variance-covariance matrix) and the estimated value of the parameter [19],

$$\text{RSE} = \frac{\text{s.e.}(\hat{\theta})}{\hat{\theta}}, \quad \theta \text{ a parameter,}$$

$$\hat{\theta} \text{ its estimated value.} \quad (4)$$

A large RSE indicates a poor estimation of the parameter.

- the η -shrinkage value (denoted throughout this manuscript as the *shrinkage* value), defined as

$$\eta\text{-shrinkage} = 1 - \frac{\text{var}(\eta_i)}{\omega^2}, \quad (5)$$

where $\text{var}(\eta_i)$ is the empirical variance of the random effect η_i and ω^2 the estimated variance of the parameter; Large values of the shrinkage characterize individual estimates shrunk towards the conditional mode of the parameter distribution.

We decided not to consider the mathematical notion of identifiability here. Indeed, studying identifiability in nonlinear mixed effect models is a complicated, open question that has been discussed for instance in [44]. Approaches based on the Fisher Information Matrix (RSE) have been proposed and are often used for evaluating identifiability of population parameters, while analysis of the shrinkage allows to investigate individual parameters identifiability, and we used such methods in this work.

Generation of synthetic data. Using a dynamical model (here System (3)), we generate a set of data associated to solutions of the model, where all the parameters are drawn from known log-normal distributions. Parameters p_k varying in the population satisfy $\log(p_k) \sim \mathcal{N}(\log(m_k), 0.1^2)$. The standard

deviation is fixed to the value 0.1 to generate heterogeneity, and values of medians m_k are given in Table A.1. A multiplicative white noise modifies model's outputs in order to mimic real measurements (we consider a white noise with standard deviation 0.2).

These data consist of time points and measurements for the 4 subpopulations of CD8 T cell counts (in log10 scale) and the immunogen load. These are called *synthetic data*, and these sets of data are referred to as Synth data set X, with $X=1, \dots, 4$ (Table 1).

We generate synthetic data for 100 individuals, cell counts are sampled at days 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30pi (cf. Figures A1 to A4). In agreement with real biological data, we assume that all cell counts below 100 cells are not measured, and remove the data. For the immunogen load, values lower than 0.1 are also not considered.

Model selection. Model selection on synthetic data is performed in 4 steps:

Step 1 Select an initial model

Step 2 Estimate parameter values using SAEM [30]

Step 3 Remove (priority list):

- parameters whose estimated value is different from their true value, and the RSE is larger than 5%
- random effects of parameters with shrinkage larger than 30%.

Step 4 Select a model with all parameters correctly estimated

In Step 1, model (3) is used, with all parameters varying within the population. This makes 29 parameters to estimate: 12 mean values, 12 random effects, 5 error parameters.

In Step 3, based on the estimations performed in Step 2, we iteratively remove parameters that are not correctly estimated. To do so, we first focus on parameters that are not estimated to their true value (which is known) and whose RSE is larger than 5% (this threshold corresponds to a 5% error on the estimated value, see (4)). We consider that the estimated value is different from the true value if $\mathcal{E}_{rr} > 10\%$, with

$$\mathcal{E}_{rr} = \frac{|\text{true value} - \text{estimated value}|}{\text{true value}}.$$

Once all parameters are correctly estimated according to the two first criteria, we remove random effects of parameters with shrinkage larger than 30% (Savic

and Karlsson [45] have shown that shrinkage can generate false correlations between random effects, or mask the existing correlations, starting from 30% shrinkage).

One must note that every time a parameter is removed from the model (mean value or random effect) then new synthetic data are generated using the same protocol as described above, and Step 2 is performed again.

Errors are known when using synthetic data: since a normal noise, proportional to the observation, modifies each observation then there is a constant error on observations of cell counts in log10 scale, and a proportional error on the immunogen load. As mentioned in Section 4.4, we assume a constant error for all cell populations and a proportional error for the immunogen load. Diagnostic tools in [30] show that error models are correct (not shown here).

Quality of fit criteria do not provide relevant information in our case: the Bayesian Information Criterion (BIC) reaches very low values, even for the initial model (3), whereas observations vs prediction graphs show that the number of outliers is not modified by simplifications of the model. Hence, we do not use quality of fit criteria to select a model. In Step 4, we select a model based on the chosen criteria that insures the correct estimation of all its parameters and its reduced shrinkage when confronted to a set of synthetic data.

4.7. Model selection on biological data

Biological data are the ones introduced in Section 4.2. Compared to synthetic data, we do not know the parameter values that would characterize them and they provide less observations, hence it may not be possible to correctly estimate as many parameters as in the synthetic data case.

Model selection on biological data is also performed in 4 steps:

Step 1 Select an initial model

Step 2 Estimate parameter values using SAEM [30]

Step 3 Remove (priority list):

- parameters whose RSE is larger than 100%
- random effects of parameters with shrinkage larger than 75%

Step 4 Select a model with RSE and shrinkages low

In Step 1, model (1) is used, with all parameters varying within the population. This makes 23

parameters to estimate: 9 mean values, 9 random effects, 5 error parameters. This model is the one selected on synthetic data (see Section 2.1).

In Step 3, we iteratively remove parameters that are not correctly estimated. We first focus on parameters that are not estimated with a high confidence, that is $RSE > 100\%$. Once all parameters are correctly estimated, we remove random effects of parameters with shrinkage larger than 75%. Noticeably, we cannot use the same threshold values for the RSE and the shrinkage when using either synthetic or real data, because measurement errors are different: controlled and known for synthetic data, uncontrolled and a priori unknown for real data, with measurement uncertainties.

The error model is not known, so we use the same error model as for synthetic data: a constant error for all cell populations (note that no data on immunogen is available, so the error parameter for the immunogen is not estimated). Diagnostic tools in [30] show that assuming constant error models is acceptable (not shown here).

4.8. A posteriori model validation on biological data

In Section 2.4, the model selected on biological data is compared to data that were not used for parameter estimation. These data are presented hereafter.

In order to assess the model ability to characterize and predict immune response dynamics we compare our results to additional experiments, VV data set 2 and Tumor data set 2 (see Table 1 and Section 4.2), similar to the ones used to estimate parameters (VV and Tumor data sets 1). CD8 T cell counts of naive, early and late effector, and memory cells have been measured following VV and Tumor immunizations, on days 4, 6, 7, 8, 11, 13, 15, 21, 28, 42pi.

The probability distribution of parameters (mean values, random effects) are known since we have estimated them on VV and Tumor data sets 1 (Section 4.7). These parameters are not estimated on the validation data. We use them to estimate the individual parameter values that fit individual behaviors of these new data sets (see Section 4.5).

Acknowledgments

The authors are grateful to Pr. Adeline Leclercq Samson for sharing her expertise on nonlinear mixed effects models. We thank the BioSyL Federation and

the LabEx Ecofect (ANR-11-LABX-0048) of the University of Lyon for inspiring scientific events. This work was supported by Inria PRE MEMOIRE grant and by the ANR predivac grant (ANR-12-RPIB-0011-01). We acknowledge the contributions of SFR Biosciences (UMS3444/CNRS, US8/Inserm, ENS de Lyon, UCBL) and of the CELPHEDIA Infrastructure (<http://www.celphedia.eu/>), especially the center AniRA in Lyon (AniRA-PBES and AniRA-Cytometrie facilities).

Author Contributions

Chloe Audebert designed the model, performed all simulations and analyses, and wrote the manuscript. Daphne Laubreton performed the experimental work, reviewed and edited the manuscript. Christophe Arpin conceived the study and designed the experiments, reviewed and edited the paper. Olivier Gandrillon contributed to models' analyses, reviewed and edited the manuscript. Jacqueline Marvel conceived the study, designed the experiments, reviewed and edited the manuscript. Fabien Crauste helped designing the model and analyzing the results, wrote the paper, and secured the funding.

References

- [1] A. Fischer and A. Rausell, Primary immunodeficiencies suggest redundancy within the human immune system, *Sci Immunol* **1** (2016), eaah5861.
- [2] H.S. Wong and R.N. Germain, Robust control of the adaptive immune system, *Semin Immunol* **36** (2018), 17–27.
- [3] M.J. Estcourt, S. Létourneau, A.J. McMichael and T. Hanke, Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses, *Eur J Immunol* **35** (2005), 2532–2540.
- [4] Z. Xiao, J.M. Curtsinger, M. Prlic, S.C. Jameson and M.F. Mescher, The CD8 T cell response to vaccinia virus exhibits site-dependent heterogeneity of functional responses, *Int Immunol* **19** (2007), 733–743.
- [5] A. Iwasaki and R. Medzhitov, Control of adaptive immunity by the innate immune system, *Nat Immunol* **16** (2015), 343–353.
- [6] O. Feinerman, J. Veiga, J.R. Dorfman, R.N. Germain and G. Altan-Bonnet, Variability and robustness in T cell activation from regulated heterogeneity in protein levels, *Science* **321** (2008), 1081–1084.
- [7] C.L. Althaus, V.V. Ganusov and R.J. De Boer, Dynamics of CD8+ T cell responses during acute and chronic lymphocytic choriomeningitis virus infection, *J Immunol* **179**(5) (2007), 2944–2951.
- [8] M. Grau, S. Valsesia, J. Mafille, S. Djebali, M. Tomkowiak, A.L. Mathieu, D. Laubreton, S. de Bernard, P.E. Jouve, E. Ventre, L. Buffat, T. Walzer, Y. Leverrier and J. Marvel,

- Antigen-Induced but Not Innate Memory CD8 T Cells Express NKG2D and Are Recruited to the Lung Parenchyma upon Viral Infection, *J Immunol* **200**(10) (2018), 3635–3646.
- [9] K. Murali-Krishna, J.D. Altman, M. Suresh, D.J. Sourdive, A.J. Zajac, J.D. Miller, J. Slansky and R. Ahmed, Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection, *Immunity* **8**(2) (1998), 177–187.
- [10] F. Crauste, J. Mafille, L. Boucinha, S. Djebali, O. Gandrillon, J. Marvel and C. Arpin, Identification of nascent Memory CD8 T cells and modeling of their ontogeny, *Cell Syst* **4**(3) (2017), 306–317.
- [11] B. Youngblood, J.S. Hale, H.T. Kissick, E. Ahn, X. Xu, A. Wieland, K. Araki, E.E. West, H.E. Ghoneim, Y. Fan, P. Dogra, C.W. Davis, B.T. Konieczny, R. Antia, X. Cheng and R. Ahmed, Effector CD8 T cells dedifferentiate into long-lived memory cells, *Nature* **552**(7685) (2017), 404–409.
- [12] J.D. Miller, R.G. van der Most, R.S. Akondy, J.T. Glidewell, S. Albott, D. Masopust, K. Murali-Krishna, P.L. Mahar, S. Edupuganti, S. Lalor, S. Germon, C. Del Rio, M.J. Mulligan, S.I. Staprans, J.D. Altman, M.B. Feinberg and R. Ahmed, Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines, *Immunity* **28**(5) (2008), 710–722.
- [13] M.L. Precopio, M.R. Betts, J. Parrino, D.A. Price, E. Gostick, D.R. Ambrozak, T.E. Asher, D.C. Douek, A. Harari, G. Pantaleo, R. Bailer, B.S. Graham, M. Roederer and R.A. Koup, Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses, *J Exp Med* **204**(6) (2007), 1405–1416.
- [14] A. Ferraro, A.M. D’Alise, T. Raj, N. Asinowski, R. Phillips, A. Ergun, J.M. Replogle, A. Bernier, L. Laffel, B.E. Stranger, P.L. De Jager, D. Mathis and C. Benoist, Interindividual variation in human T regulatory cells, *Proc Nat Acad Sci* **111**(12) (2014), 1111–1120.
- [15] Y. Li, M. Oosting, P. Deelen, I. Rica no-Ponce, S. Smeekens, M. Jaeger, V. Matzaraki, M.A. Swertz, R.J. Xavier, L. Franke, C. Wijmenga, L. Joosten, V. Kumar and M.G. Netea, Interindividual variability and genetic influences on cytokine responses to bacteria and fungi, *Nature Medicine* **22**(8) (2016), 952.
- [16] V.P. Badovinac, J.S. Haring and J.T. Harty, Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T cell response to infection, *Immunity* **26**(6) (2007), 827–841.
- [17] B. Delyon, M. Lavielle and E. Moulines, Convergence of a stochastic approximation version of the EM algorithm, *The Annals of Stat* **27**(1) (1999), 94–128.
- [18] E. Kuhn and M. Lavielle, Maximum likelihood estimation in nonlinear mixed effects models, *Computational Statistics and Data Analysis* **49**(4) (2005), 1020–1038.
- [19] M. Lavielle, Mixed effects models for the population approach. Models, Tasks, Methods and Tools, *Chapmann and Hall/CRC*, (2014), pp. 383.
- [20] M. Davidian and D.M. Giltinan, Nonlinear models for repeated measurement data: An overview and update, *J Agric Biol Environ Stat* **8** (2003), 387–419.
- [21] J. Almquist, L. Bendrioua, C.B. Adiels, Goksör M, S. Hohmann and M. Jirstrand, A Nonlinear Mixed Effects Approach for Modeling the Cell-To-Cell Variability of Mig1 Dynamics in Yeast, *PLoS ONE* **10**(4) (2015), e0124050.
- [22] A. Llamosi, A.M. Gonzalez-Vargas, C. Versari, E. Cinquemani, G. Ferrari-Trecate, P. Hersen and G. Batt, What Population Reveals about Individual Cell Identity: Single Cell Parameter Estimation of Models of Gene Expression in Yeast, *PLoS Comput Biol* **12**(2) (2016), 1553–7358.
- [23] S. Benzekry, C. Lamont, A. Beheshti, A. Tracz, J.M.L. Ebos, L. Hlatky and P. Hahnfeldt, Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth, *PLoS Comput Biol* **10**(8) (2014), e1003800.
- [24] T. Ferenci, J. Sápi and L. Kovács, Modelling tumor growth under angiogenesis inhibition with mixed-effects models, *Acta Polytechnica Hungarica* **14** (2017), 221–234.
- [25] N. Keersmaekers, B. Ogunjimi, P. Van Damme, P. Beutels and N. Hens, An ODE-based mixed modelling approach for B- and T-cell dynamics induced by Varicella-Zoster Virus vaccines in adults shows higher T-cell proliferation with Shingrix than with Varilrix, *Vaccine* **37** (2019), 2537–2553.
- [26] A. Jarne, D. Commenges, M. Prague, Y. Levy and R. Thiébaud, Modeling CD4+ T cells dynamics in HIV-infected patients receiving repeated cycles of exogenous Interleukin 7, *The Annals of Applied Statistics* **11**(3) (2017), 1593–1616.
- [27] L. Villain, D. Commenges, C. Pasin, M. Prague and R. Thiébaud, Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts, *Statistics in Medicine* **38**(2) (2018), 221–235.
- [28] R.J. De Boer, M. Oprea, R. Antia, K. Murali-Krishna, R. Ahmed and A.S. Perelson, Recruitment times, proliferation, and apoptosis rates during the CD8 + T-cell response to lymphocytic choriomeningitis virus, *J Virol* **75** (2001), 10663–10669.
- [29] R. Antia, C.T. Bergstrom, S.S. Pilyugin, S.M. Kaech and R. Ahmed, Models of CD8 + responses: 1. What is the antigen-independent proliferation program, *J Theor Biol* **221** (2003), 585–598.
- [30] Monolix version 2019R1. Antony, France: Lixoft SAS, 2019.
- [31] I.M. Sobol, Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates, *Mathematics and Computers in Simulation* **55**(1-3) (2001), 271–280.
- [32] K. Thomaseth and C. Cobelli, Generalized Sensitivity Functions in Physiological System Identification, *Annals of Biomedical Engineering* **27** (1999), 607–616.
- [33] J.W. van Heijst, C. Gerlach, E. Swart, D. Sie, C. Nunes-Alves, R.M. Kerkhoven, R. Arens, M. Correia-Neves, K. Schepers and T.N. Schumacher, Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient, *Science* **325**(5945) (2009), 1265–1269.
- [34] S. Kaech and R. Ahmed, Memory CD8+ T cell differentiation : initial antigen encounter triggers a developmental program in nave cells, *Nat Immunol* **2** (2001), 415–422.
- [35] M.V. Stipdonk, E. Lemmens and S. Schoenberger, Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation, *Nat Immunol* **2** (2001), 423–429.
- [36] D. Yang, Z. Han and J.J. Oppenheim, Alarmins and immunity, *Immunol Rev* **280** (2017), 41–56.
- [37] M.F. Mescher, J.M. Curtsinger, P. Agarwal, K.A. Casey, M. Gerner, C.D. Hammerbeck, F. Popescu and Z. Xiao, Signals required for programming effector and memory development by CD8+ T cells, *Immunol Rev* **211** (2006), 81–92.
- [38] V. Jubin, E. Ventre, Y. Leverrier, S. Djebali, K. Mayol, M. Tomkowiak, J. Mafille, M. Teixeira, D.Y.L. Teoh, B. Lina, et al., T inflammatory memory CD8 T cells participate to antiviral response and generate secondary memory cells with an advantage in XCL1 production, *Immunol Res* **52** (2012), 284–293.

- 1292 [39] C. de Brito, M. Tomkowiak, R. Ghittoni, C. Caux, Y. Lev- 1306
1293 errier and J. Marvel, CpG promotes cross-presentation of 1307
1294 dead cell-associated antigens by pre-CD8a+ dendritic cells 1308
1295 [corrected], *J Immunol* **186** (2011), 1503–1511. 1309
- 1296 [40] F. Crauste, E. Terry, I. Le Mercier, J. Mafille, S. Djebali, 1310
1297 T. Andrieu, B. Mercier, G. Kaneko, C. Arpin, J. Marvel 1311
1298 and O. Gandrillon, Predicting pathogen-specific CD8 T cell 1312
1299 immune responses from a modeling approach, *J Theoret 1313*
1300 *Biol* **374** (2015), 66–82. 1314
- 1301 [41] R. Kemp, T. Powell, D. Dwyer and R. Dutton, Cutting 1315
1302 edge: regulation of CD8+ T cell effector population size, 1306
1303 *J Immunol* **173** (2004), 2923–2927. 1307
- 1304 [42] M. Su, P. Wladen, D. Golan and H. Eisen, Cognate peptide- 1308
1305 induced destruction of CD8+ cytotoxic T lymphocytes is 1309
due to fratricide, *J Immunol* **151** (1993), 658–667. 1310
- [43] A. Samson and S. Donnet, Estimation of parameters in 1311
incomplete data models defined by dynamical systems, 1312
Journal of Statistical Planning and Inference **137**(9) (2007), 1313
2815–2831. 1314
- [44] M. Lavielle and L. Aarons, What do we mean by identifiability 1315
in mixed effects models? *J Pharmacokinet Pharmacodyn* 1306
43(1) (2016), 111–122. 1307
- [45] R. Savic and M. Karlsson, Importance of Shrinkage in 1308
Empirical Bayes Estimates for Diagnostics: Problems and 1309
Solutions. In: *AAPS J* **11**(3) (2009), pp. 558–569. 1310

Uncorrected Author Proof

1316 **A. Appendices**1317 *A1 Parameter values used to generate synthetic data sets*

1318 Table A1 lists parameter values used to generate Synth data sets 1 to 4 (see Table 1). Figures A1 to A4 illustrate
 1319 Synth data sets 1 to 4 kinetics.

Table A1

Parameter values of fixed effects (median values) used to generate Synth data sets 1 to 4 from System (3) and its subsequent reductions: removal of μ_I^E (column 4), of μ_L^E (column 5), and of μ_I (column 6). Notations μ_X^Y for some mortality-related parameters refer to parameters μ_{XY} in [10]: the subscript X refers to the CD8 T cell population or the immunogen that dies, and the superscript Y to the CD8 T cell population responsible for inducing death

Parameter	Unit	Synth data set			
		1	2	3	4
μ_N	day ⁻¹	0.75	0.75	0.75	0.75
δ_{NE}	day ⁻¹	0.009	0.009	0.009	0.009
ρ_E	day ⁻¹	0.64	0.64	0.64	0.64
μ_E^E	10 ⁻⁶ cell ⁻¹ day ⁻¹	21.5	21.5	21.5	21.5
δ_{EL}	day ⁻¹	0.59	0.59	0.59	0.59
μ_I^L	10 ⁻⁶ cell ⁻¹ day ⁻¹	7.5	7.5	7.5	7.5
μ_L^E	10 ⁻⁸ cell ⁻¹ day ⁻¹	3.6	3.6	-	-
δ_{LM}	day ⁻¹	0.025	0.025	0.025	0.025
ρ_I	day ⁻¹	0.1	0.1	0.1	0.1
μ_I^E	10 ⁻⁷ cell ⁻¹ day ⁻¹	1.8	-	-	-
μ_I^L	10 ⁻⁵ cell ⁻¹ day ⁻¹	1.8	1.8	1.8	1.8
μ_I	day ⁻¹	0.055	0.055	0.055	-




Fig. A1. Synth data set 1. These data have been obtained by simulating System (3) with parameter values in Table A1 and using a multiplicative white noise, as detailed in Section 4.6. 100 individuals are simulated and first observations are on day 4 pi for cell populations and the immunogen. Then measurements are on days 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, and 30 pi. All cell counts below 100 cells are not measured. For the immunogen load, values lower than 0.1 are also not considered.




Fig. A2. Synth data set 2. These data have been obtained by simulating a reduced System (3), with parameter values in Table A1, and using a multiplicative white noise, as detailed in Section 4.6. See Figure A1 for details.




Fig. A3. Synth data set 3. These data have been obtained by simulating a reduced System (3), with parameter values in Table A1, and using a multiplicative white noise, as detailed in Section 4.6. See Figure A1 for details.




Fig. A4. Synth data set 4. These data have been obtained by simulating a reduced System (3), with parameter values in Table A1, and using a multiplicative white noise, as detailed in Section 4.6. See Figure A1 for details.

1320 *A2 Parameter value estimation using Synth data sets 1 to 4*

1321 Table A2 presents the different steps in estimating parameter values using Synth data sets 1 to 4 and System
 1322 (3). The procedure is detailed in Section 4.6.

Table A2

Steps in estimating parameter values using Synth data sets 1 to 4 and System (3). The procedure is detailed in Section 4.6. True values of parameters (fixed effects) are given on the second line, true values of random effects all equal 0.1. At *Step 1*, the procedure leads to removing parameter μ_I^E . At *Step 2*, the procedure leads to removing parameter μ_L^E . At *Step 3*, the procedure leads to removing parameter μ_I . At *Step 4*, no other action is required. Values used to take a decision are highlighted in bold at each step. In the first column, 'm.v.' stands for mean value, RSE is defined in (4), 'r.e.' stands for random effect, and the shrinkage is defined in (5). Note that values (mean values and random effects) of parameters μ_E^E , μ_L^L , μ_I^E , μ_I^L and μ_I have to be multiplied by 10^{-5} (for μ_I^L), 10^{-6} (for μ_E^E and μ_L^L), 10^{-7} (for μ_I^E), and 10^{-8} (for μ_I^L). Units are omitted for the sake of clarity

Parameters	μ_N	δ_{NE}	ρ_E	μ_E^E	δ_{EL}	μ_L^L	μ_L^E	δ_{LM}	ρ_I	μ_I^E	μ_I^L	μ_I
True values	0.75	0.009	0.64	21.5	0.59	7.5	3.6	0.025	0.1	1.8	1.8	0.055
<i>Step 1</i>												
m.v.	0.75	0.009	0.60	15.8	0.59	7.5	0.9	0.024	0.07	0.2	1.8	0.012
RSE	1	2	2	4	2	2	21	3	2	61	3	11
r.e.	0.1	0.2	0.2	0.3	0.2	0.2	0.7	0.3	0.2	2	0.3	0.9
RSE	7	7	7	8	7	7	23	7	8	21	7	11
shrinkage	-1	8	12	18	13	1	100	-1	39	96	4	82
<i>Step 2</i>												
m.v.	0.76	0.009	0.59	17.2	0.58	7.9	0.3	0.024	0.07	-	1.9	0.012
RSE	1	2	2	4	2	2	17	3	2	-	3	11
r.e.	0.1	0.2	0.2	0.3	0.2	0.2	0.5	0.3	0.2	-	0.3	0.9
RSE	7	7	7	8	7	7	26	7	8	-	7	10
shrinkage	-1	10	12	20	15	1	100	-1	46	-	4	80
<i>Step 3</i>												
m.v.	0.75	0.01	0.59	17.0	0.58	7.8	-	0.025	0.07	-	1.8	0.013
RSE	1	2	2	3	2	2	-	3	3	-	3	9
r.e.	0.1	0.2	0.2	0.3	0.2	0.2	-	0.3	0.2	-	0.3	0.7
RSE	7	7	7	8	7	7	-	7	8	-	7	10
shrinkage	-1	8	11	17	13	1	-	-1	34	-	2	82
<i>Step 4</i>												
m.v.	0.76	0.009	0.66	21.2	0.61	7.3	-	0.024	0.1	-	1.8	-
RSE	1	2	1	2	1	2	-	3	1	-	2	-
r.e.	0.1	0.2	0.1	0.2	0.1	0.2	-	0.3	0.1	-	0.2	-
RSE	7	7	7	7	7	7	-	7	7	-	7	-
shrinkage	-1	3	6	6	7	-1	-	-1	0	-	1	-

1323 *4.9. A3. Predicted individual dynamics from VV and Tumor data sets 2*

1324 Predicted individual dynamics from VV and Tumor data sets 2, discussed in Section 2.4, are available at
 1325 <https://plmlab.math.cnrs.fr/audebert/cd8-responses>.